• VIDEO: New treatment option for rare cardiomyopathy may 'change lives'

    7 monthes ago - By Healio

    MUNICH - In this Cardiology Today video exclusive, Martha Gulati, MD, MS, FACC, FAHA, offers her highlights from the European Society of Cardiology Congress, including the ATTR-ACT and SCOT-HEART trials.
    ATTR-ACT, which showed tafadamis improved outcomes in patients with certain types of transthyretin amyloid cardiomyopathy, is the trial from ESC Congress “that I think is going to change lives the most,” Gulati, division chief of cardiology for the University of Arizona College of Medicine - Phoenix and physician executive director for the Banner
    Read more ...